Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 517

1.

Real-World Data and Randomised Controlled Trials: The Salford Lung Study.

Leather DA, Jones R, Woodcock A, Vestbo J, Jacques L, Thomas M.

Adv Ther. 2020 Jan 11. doi: 10.1007/s12325-019-01192-1. [Epub ahead of print] Review.

PMID:
31927698
2.

The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma.

Eguiluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJ, Fuertes E, Comberiati P, Cai YS, Tomazic PV, Diamant Z, Vestbo J, Galan C, Hoffmann B.

Allergy. 2020 Jan 9. doi: 10.1111/all.14177. [Epub ahead of print]

PMID:
31916265
3.

Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study.

Meszaros M, Tarnoki AD, Tarnoki DL, Kovacs DT, Forgo B, Lee J, Sung J, Vestbo J, Müller V, Kunos L, Bikov A.

J Sleep Res. 2020 Jan 6:e12979. doi: 10.1111/jsr.12979. [Epub ahead of print]

PMID:
31908118
4.

Fraction of exhaled nitric oxide levels are elevated in people living with HIV compared to uninfected controls suggesting increased eosinophilic airway inflammation.

Thudium RF, Hughes NLP, Afzal S, Çolak Y, Gelpi M, Knudsen AD, Kirkegaard-Klitbo DM, Borges ÁH, Gerstoft J, Nordestgaard BG, Vestbo J, Lundgren J, Ronit A, Nielsen SD.

Clin Infect Dis. 2020 Jan 4. pii: ciz1223. doi: 10.1093/cid/ciz1223. [Epub ahead of print]

PMID:
31900471
5.

ERS and tobacco harm reduction.

Pisinger C, Dagli E, Filippidis FT, Hedman L, Janson C, Loukides S, Ravara S, Saraiva I, Vestbo J; ERS Tobacco Control Committee, on behalf of the ERS.

Eur Respir J. 2019 Dec 4;54(6). pii: 1902009. doi: 10.1183/13993003.02009-2019. Print 2019 Dec. No abstract available.

PMID:
31801824
6.

Prevalence, Characteristics, and Prognosis of Early COPD: The Copenhagen General Population Study.

Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P.

Am J Respir Crit Care Med. 2019 Nov 26. doi: 10.1164/rccm.201908-1644OC. [Epub ahead of print]

PMID:
31770495
7.

A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations.

Mathioudakis AG, Janner J, Moberg M, Alonso-Coello P, Vestbo J.

ERJ Open Res. 2019 Nov 15;5(4). pii: 00136-2019. doi: 10.1183/23120541.00136-2019. eCollection 2019 Oct.

8.

End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort.

Manon-Jensen T, Langholm LL, Rønnow SR, Karsdal MA, Tal-Singer R, Vestbo J, Leeming DJ, Miller BE, Bülow Sand JM.

Respir Med. 2019 Nov - Dec;160:105814. doi: 10.1016/j.rmed.2019.105814. Epub 2019 Nov 6.

PMID:
31739246
9.

The Pressing Need to Redefine "COPD".

Barnes PJ, Vestbo J, Calverley PM.

Chronic Obstr Pulm Dis. 2019 Nov;6(5):380-383. doi: 10.15326/jcopdf.6.5.2019.0173. No abstract available.

10.

β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study.

Ingebrigtsen TS, Vestbo J, Rode L, Marott JL, Lange P, Nordestgaard BG.

Thorax. 2019 Oct;74(10):934-940. doi: 10.1136/thoraxjnl-2018-212340. Epub 2019 Sep 3.

PMID:
31481635
11.

Prognosis of COPD depends on severity of exacerbation history: A population-based analysis.

Çolak Y, Afzal S, Marott JL, Nordestgaard BG, Vestbo J, Ingebrigtsen TS, Lange P.

Respir Med. 2019 Aug;155:141-147. doi: 10.1016/j.rmed.2019.07.021. Epub 2019 Jul 25.

PMID:
31362177
12.

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.

Celli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, Dixon I, Kim V, Martinez FJ, Morris A, Newby DE, Yates J, Vestbo J.

BMJ Open Respir Res. 2019 May 4;6(1):e000431. doi: 10.1136/bmjresp-2019-000431. eCollection 2019.

13.

Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry.

Çolak Y, Nordestgaard BG, Vestbo J, Lange P, Afzal S.

Eur Respir J. 2019 Sep 19;54(3). pii: 1900734. doi: 10.1183/13993003.00734-2019. Print 2019 Sep.

PMID:
31248954
14.

Accuracy of Airflow Obstruction Thresholds for Predicting COPD-Related Hospitalization and Mortality: Can Simple Diagnostic Thresholds Be Used for a Complex Disease?

Vestbo J, Lange P.

JAMA. 2019 Jun 25;321(24):2412-2413. doi: 10.1001/jama.2019.6584. No abstract available.

PMID:
31237620
15.

COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months.

Sivapalan P, Ingebrigtsen TS, Rasmussen DB, Sørensen R, Rasmussen CM, Jensen CB, Allin KH, Eklöf J, Seersholm N, Vestbo J, Jensen JS.

BMJ Open Respir Res. 2019 Mar 30;6(1):e000407. doi: 10.1136/bmjresp-2019-000407. eCollection 2019.

16.

Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.

Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklöf J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brøndum E, Sonne TP, Rønholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS.

Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20.

PMID:
31122894
17.

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.

18.

Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials.

Mathioudakis AG, Moberg M, Janner J, Alonso-Coello P, Vestbo J.

ERJ Open Res. 2019 May 10;5(2). pii: 00072-2019. doi: 10.1183/23120541.00072-2019. eCollection 2019 Apr.

19.

Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients.

Johansson SL, Wulf-Johansson H, Schlosser A, Titlestad IL, Miller B, Tal-Singer R, Holmskov U, Vestbo J, Sørensen GL.

ERJ Open Res. 2019 Apr 15;5(2). pii: 00021-2019. doi: 10.1183/23120541.00021-2019. eCollection 2019 Apr.

20.

Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort.

Rønnow SR, Sand JMB, Langholm LL, Manon-Jensen T, Karsdal MA, Tal-Singer R, Miller BE, Vestbo J, Leeming DJ.

Respir Res. 2019 Apr 1;20(1):63. doi: 10.1186/s12931-019-1026-x.

21.

Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT.

Celli BR, Anderson JA, Brook RD, Calverley PMA, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Vestbo J.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900278. doi: 10.1183/13993003.00278-2019. Print 2019 Jun. No abstract available.

PMID:
30923182
22.

Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration.

Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA; on behalf of the CADSET Clinical Research Collaboration; Current members of the CADSET Clinical Research Collaboration.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900217. doi: 10.1183/13993003.00217-2019. Print 2019 Mar. No abstract available.

PMID:
30886026
23.

Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort.

Rønnow SR, Langholm LL, Sand JMB, Thorlacius-Ussing J, Leeming DJ, Manon-Jensen T, Tal-Singer R, Miller BE, Karsdal MA, Vestbo J.

Sci Rep. 2019 Mar 11;9(1):4064. doi: 10.1038/s41598-019-40785-2.

24.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
25.

Association of Cardiovascular Disease With Respiratory Disease.

Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, Chaudhuri N, Schelbert EB, Potluri R, Miller CA.

J Am Coll Cardiol. 2019 May 7;73(17):2166-2177. doi: 10.1016/j.jacc.2018.11.063. Epub 2019 Mar 4.

PMID:
30846341
26.

Was the implementation strategy of the ProACT trial adequately proactive?

Mathioudakis AG, Vestbo J.

Breathe (Sheff). 2019 Mar;15(1):77-80. doi: 10.1183/20734735.0338-2018.

27.

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.

Vestbo J, Dransfield M, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Lange P.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00203-2018. doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.

28.

Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.

Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat M, Wyss AB, Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, de Jong K, DeMeo DL, Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, Hokanson JE, Kim WJ, Lomas DA, London SJ, Meyers DA, O'Connor GT, Rennard SI, Schwartz DA, Sliwinski P, Sparrow D, Strachan DP, Tal-Singer R, Tesfaigzi Y, Vestbo J, Vonk JM, Yim JJ, Zhou X, Bossé Y, Manichaikul A, Lahousse L, Silverman EK, Boezen HM, Wain LV, Tobin MD, Hobbs BD, Cho MH; SpiroMeta Consortium; International COPD Genetics Consortium.

Nat Genet. 2019 Mar;51(3):494-505. doi: 10.1038/s41588-018-0342-2. Epub 2019 Feb 25.

29.

Prospective observational study in patients with obstructive lung disease: NOVELTY design.

Reddel HK, Gerhardsson de Verdier M, Agustí A, Anderson G, Beasley R, Bel EH, Janson C, Make B, Martin RJ, Pavord I, Price D, Keen C, Gardev A, Rennard S, Sveréus A, Bansal AT, Brannman L, Karlsson N, Nuevo J, Nyberg F, Young SS, Vestbo J.

ERJ Open Res. 2019 Feb 1;5(1). pii: 00036-2018. doi: 10.1183/23120541.00036-2018. eCollection 2019 Feb.

30.

Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.

Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.

Respir Med. 2019 Feb;147:58-65. doi: 10.1016/j.rmed.2018.12.016. Epub 2019 Jan 10.

31.

Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.

Pilecki B, Wulf-Johansson H, Støttrup C, Jørgensen PT, Djiadeu P, Nexøe AB, Schlosser A, Hansen SWK, Madsen J, Clark HW, Nielsen CH, Vestbo J, Palaniyar N, Holmskov U, Sorensen GL.

Front Immunol. 2018 Dec 18;9:3013. doi: 10.3389/fimmu.2018.03013. eCollection 2018.

32.

Automated oxygen control with O2matic® during admission with exacerbation of COPD.

Hansen EF, Hove JD, Bech CS, Jensen JS, Kallemose T, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 14;13:3997-4003. doi: 10.2147/COPD.S183762. eCollection 2018.

33.

The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation.

Khan N, Vestbo J, Garrow A, Karur P, Kolsum U, Tyson S, Singh D, Yorke J.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 29;13:3885-3894. doi: 10.2147/COPD.S171140. eCollection 2018.

34.

What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.

Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 23;13:3485-3492. doi: 10.2147/COPD.S173664. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2018 Dec 05;13:3899.

35.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
36.

Validation of lung density indices by cardiac CT for quantification of lung emphysema.

Ronit A, Kristensen T, Çolak Y, Kühl JT, Kalhauge A, Lange P, Nordestgaard BG, Vestbo J, Nielsen SD, Kofoed KF.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 11;13:3321-3330. doi: 10.2147/COPD.S172695. eCollection 2018.

37.

Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.

Papi A, Singh D, Petruzzelli S, Guasconi A, Vestbo J.

Lancet. 2018 Sep 29;392(10153):1113-1114. doi: 10.1016/S0140-6736(18)31778-1. No abstract available.

PMID:
30303077
38.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
39.

Inhaled corticosteroids in COPD: friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801219. doi: 10.1183/13993003.01219-2018. Print 2018 Dec. Review.

PMID:
30190269
40.

Childhood Asthma, Lung Function Trajectories, and Chronic Obstructive Pulmonary Disease: An Additional Step Forward.

Vestbo J.

Ann Am Thorac Soc. 2018 Sep;15(9):1030-1031. doi: 10.1513/AnnalsATS.201807-440ED. No abstract available.

PMID:
30168747
41.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL.

J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137. doi: 10.1016/j.jacc.2018.06.051. Erratum in: J Am Coll Cardiol. 2018 Oct 30;72(18):2282.

42.

Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls.

Ronit A, Benfield T, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group.

HIV Med. 2018 Nov;19(10):751-755. doi: 10.1111/hiv.12669. Epub 2018 Aug 30.

PMID:
30160344
43.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD; SUMMIT Investigators.

Eur Heart J. 2018 Sep 1;39(33):3128-3134. doi: 10.1093/eurheartj/ehy451.

PMID:
30101300
44.

Whole exome sequencing analysis in severe chronic obstructive pulmonary disease.

Qiao D, Ameli A, Prokopenko D, Chen H, Kho AT, Parker MM, Morrow J, Hobbs BD, Liu Y, Beaty TH, Crapo JD, Barnes KC, Nickerson DA, Bamshad M, Hersh CP, Lomas DA, Agusti A, Make BJ, Calverley PMA, Donner CF, Wouters EF, Vestbo J, Paré PD, Levy RD, Rennard SI, Tal-Singer R, Spitz MR, Sharma A, Ruczinski I, Lange C, Silverman EK, Cho MH.

Hum Mol Genet. 2018 Nov 1;27(21):3801-3812. doi: 10.1093/hmg/ddy269.

45.

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.

Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A.

Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6.

46.

Computed tomography quantification of emphysema in people living with HIV and uninfected controls.

Ronit A, Kristensen T, Hoseth VS, Abou-Kassem D, Kühl JT, Benfield T, Gerstoft J, Afzal S, Nordestgaard BG, Lundgren JD, Vestbo J, Kofoed KF, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) study group.

Eur Respir J. 2018 Jul 19;52(1). pii: 1800296. doi: 10.1183/13993003.00296-2018. Print 2018 Jul.

47.

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP; COPDGene and ECLIPSE Investigators.

J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10. doi: 10.1016/j.jaci.2018.04.010. Epub 2018 Apr 28.

48.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

49.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
50.

Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.

Vedel-Krogh S, Nordestgaard BG, Lange P, Vestbo J, Nielsen SF.

Eur Respir J. 2018 May 24;51(5). pii: 1800120. doi: 10.1183/13993003.00120-2018. Print 2018 May.

Supplemental Content

Loading ...
Support Center